000094555 001__ 94555
000094555 005__ 20230914083303.0
000094555 0247_ $$2doi$$a10.1016/j.gore.2020.100594
000094555 0248_ $$2sideral$$a118625
000094555 037__ $$aART-2020-118625
000094555 041__ $$aeng
000094555 100__ $$aRubio, M.J.
000094555 245__ $$aEfficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
000094555 260__ $$c2020
000094555 5060_ $$aAccess copy available to the general public$$fUnrestricted
000094555 5203_ $$aObjective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracycline-containing regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5–7.3) and 18.5 months (95%CI: 11.5–25.6), respectively. Median OS was significantly higher (P = 0.028) in patients receiving trabectedin in = 2nd line (25.3 months) than in = 3rd (15.1 months) and with ECOG performance status = 1 at trabectedin start (19.8 months) than ECOG 2–3 (6.0 months, P = 0.013). When calculating OS since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy (87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radiochemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients (25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration of 11 months (range: 4–93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR) of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in = 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines. Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%). Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable safety profile.
000094555 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000094555 592__ $$a0.557$$b2020
000094555 593__ $$aOncology$$c2020$$dQ3
000094555 593__ $$aObstetrics and Gynecology$$c2020$$dQ3
000094555 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000094555 700__ $$aLecumberri, M.J.
000094555 700__ $$aVarela, S.
000094555 700__ $$aAlarcón, J.
000094555 700__ $$aOrtega, M.E.$$uUniversidad de Zaragoza
000094555 700__ $$aGaba, L.
000094555 700__ $$aEspinós, J.
000094555 700__ $$aCalzas, J.
000094555 700__ $$aBarretina, P.
000094555 700__ $$aRuiz, I.
000094555 700__ $$aMarquina, G.
000094555 700__ $$aSantaballa, A.
000094555 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000094555 773__ $$g33, 100594 (2020), 1-6$$tGynecologic Oncology Reports$$x2352-5789
000094555 8564_ $$s478919$$uhttps://zaguan.unizar.es/record/94555/files/texto_completo.pdf$$yVersión publicada
000094555 8564_ $$s66152$$uhttps://zaguan.unizar.es/record/94555/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000094555 909CO $$ooai:zaguan.unizar.es:94555$$particulos$$pdriver
000094555 951__ $$a2023-09-13-10:54:33
000094555 980__ $$aARTICLE